摘要:
본 발명은 일정 수의 아르기닌와 소수성 아미노산을 포함하는 펩티드로 형성된 펩티드 마이셀을 제공한다. 또한, 본 발명은 본 발명의 펩티드 마이셀을 포함하는 약물전달체, 결합 핵산를 더 포함하는 핵산 결합 복합체를 제공한다. 본 발명에 따르는 아르기닌 기반의 짧은 펩티드로 이루어진 펩티드 마이셀은 독성이 적고, 핵산 전달 효율은 종래 기술에서 사용이 고려되는 고분자 벡터보다 높거나 유사해서, 보다 안전한 핵산 치료제로 유용하다.
摘要:
The present invention is directed to a pharmaceutical composition in the form of tablets, which constitute an orally administered, controlled drug delivery system that will provide increased retention time of the device in the stomach over conventional dosage forms and release metformin or its pharmaceutically acceptable salt in a controllable manner, and further that is easy and inexpensive to manufacture.
摘要:
An improved ophthalmic composition comprising an anionic polymeric substance, such as Hyaluronic Acid and/or Carboxymethylcellulose, in combination with any of various cationic monomeric or dimeric antimicrobial agents, such as Cetylpyridinium Chloride and/or Alexidine Dihydrochloride, wherein said compositions provide additional comfort and biocompatibility with lenses without significantly affecting the antimicrobial efficacy of the antimicrobial agent and without therefore requiring a substantially increased concentration of the agent such as that could expose contact lens wearers to increased levels of the disinfecting agent. Solutions according to the present invention may be used for effective multipurpose contact lens disinfection compositions, lens packaging solution compositions, and/or eye drops such as rewetters and tears.
摘要:
In one embodiment, a dosage form comprises: (a) at least one active ingredient; (b) a molded core which is solid at room temperature; and (c) a shell which is in contact with at least a portion of the core, wherein the dosage form provides modified release of the active ingredient upon contacting of the dosage form with a liquid medium. In another embodiment of this invention, a dosage form comprises: (a) at least one active ingredient; (b) a molded core comprising a plurality of particles; and (c) a shell which is in contact with at least a portion of the core, wherein the dosage form provides modified release of the active ingredient upon contacting of the dosage form with a liquid medium.
摘要:
In one embodiment, the invention relates to sustained-release compositions comprising one or more prolamins, one or more gelling agents, and one or more active agents. Such compositions are particularly useful for controlled delivery of high solubility and/or high dosage active agents. In another embodiment, the present invention relates to delayed-onset compositions comprising a dry coating comprising one or more prolamins and one or more gelling agents.
摘要:
A coating for masking or reducing the detectable presence of certain characteristic odor or odors, taste or tastes of pharmaceutical preparations, particularly valerian extracts, is described. The coating comprises from at least one to three coating compartments, in any combination or as a single-layer amalgam. The first coating compartment (4) preferably comprises a hydroxyalkyl cellulose and an anti-tackiness agent. The second coating compartment (6) preferably comprises a sugar and at least one anti-tackiness agent. The third coating compartment (8) preferably comprises a methacrylate copolymer, a hydroxyalkyl cellulose and an anti-tackiness agent. An option fourth coating compartment (10) may be applied as a cosmetic color coat, need not function as an odor-masking coat, and may be combined with one or more of the other three coating compartments.
摘要:
This invention relates to a combination drug product comprising troglitazone, e.g. its hydrochloride, and a biguamide, e.g. metformin. In particular, the product comprises a core of metformin, at least a portion thereof has a layer or coat thereon of troglitazone.
摘要:
The present invention is directed to methods of controlling extracellular matrix protein microstructure in a biological composition using ultrasound technology. The invention is further directed to three-dimensional monolithic tissue scaffolds having spatially defined regions of varying extracellular matrix protein microstructure and engineered tissue constructs comprising the same.
摘要:
Methods and compositions to reduce immunogenicity of proteins are disclosed. Compositions comprising therapeutic proteins (such as Factor VIII or any other protein or peptide) complexed with liposomes comprising PS and PC (PS liposomes), or comprising PS, PI and PC and, optionally, cholesterol (PS/PI liposomes) may be used.
摘要:
지질 및 아미노산계 고분자(poly(amino acid)s)를 포함하는 고분자-리포좀 나노복합체, 및 그 제조방법을 제공한다. 상기 고분자-리포좀 나노복합체는 계면활성제와 염에 대한 제형 안정성이 우수하며, 의약 및 화장품 분야 등에서 약물전달체로서 다양하게 활용 가능하다.